Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN)
India · Delayed Price · Currency is INR 152.50
+0.83 (0.55%)
Sep 10, 2026, 3:29 PM IST
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 4,898 | 4,451 | 3,649 | 3,326 | 3,014 | 2,784 |
Other Revenue | - | 0.5 | 1.31 | 1.41 | - | - |
| 4,898 | 4,452 | 3,650 | 3,328 | 3,014 | 2,784 | |
Revenue Growth | 21.02% | 21.95% | 9.70% | 10.42% | 8.26% | -9.49% |
Cost of Revenue | 2,265 | 1,384 | 843.13 | 839.27 | 814.33 | 936.65 |
Gross Profit | 2,633 | 3,067 | 2,807 | 2,488 | 2,199 | 1,847 |
Selling, General & Admin | 1,719 | 638.79 | 522.24 | 442.11 | 372.48 | 382.11 |
Other Operating Expenses | 331.64 | 1,901 | 1,775 | 1,546 | 1,338 | 1,088 |
Operating Expenses | 2,090 | 2,580 | 2,336 | 2,021 | 1,741 | 1,501 |
Operating Income | 543.11 | 487.69 | 471.49 | 467.6 | 458.79 | 345.7 |
Interest Expense | -170.25 | -152.4 | -99 | -86.29 | -95.73 | -101.25 |
Interest & Investment Income | - | 65.32 | 35.89 | 3.23 | 0.18 | 10.93 |
Currency Exchange Gain (Loss) | - | 7.57 | 6.4 | -0.14 | 4.3 | 0.59 |
Other Non Operating Income (Expenses) | 79.16 | -5.6 | -4.39 | -3.26 | -5.93 | -3.88 |
EBT Excluding Unusual Items | 452.02 | 402.59 | 410.38 | 381.15 | 361.59 | 252.08 |
Gain (Loss) on Sale of Assets | - | 0.02 | -10.35 | 0.01 | -0.01 | 0.04 |
Asset Writedown | - | -2.44 | - | - | - | - |
Other Unusual Items | 51.44 | 60.07 | 5.4 | 34.49 | - | -887.82 |
Pretax Income | 503.45 | 463.04 | 405.84 | 415.65 | 361.64 | -634.34 |
Income Tax Expense | 47.34 | 46.73 | 19.85 | 19.46 | 11.53 | 39.52 |
Net Income | 456.11 | 416.3 | 386 | 396.19 | 350.11 | -673.85 |
Net Income to Common | 456.11 | 416.3 | 386 | 396.19 | 350.11 | -673.85 |
Net Income Growth | 7.25% | 7.85% | -2.57% | 13.16% | - | - |
Shares Outstanding (Basic) | 20 | 19 | 19 | 19 | 19 | 19 |
Shares Outstanding (Diluted) | 20 | 19 | 19 | 19 | 19 | 19 |
Shares Change | 4.21% | - | - | - | - | - |
EPS (Basic) | 22.99 | 21.91 | 20.31 | 20.85 | 18.42 | -35.46 |
EPS (Diluted) | 22.99 | 21.91 | 20.31 | 20.85 | 18.42 | -35.46 |
EPS Growth | 2.93% | 7.85% | -2.57% | 13.16% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -155.78 | 96.61 | 478.18 | 354.85 | -39.56 |
Free Cash Flow Per Share | - | -8.20 | 5.08 | 25.16 | 18.67 | -2.08 |
Dividend Per Share | - | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 53.76% | 68.90% | 76.90% | 74.78% | 72.98% | 66.35% |
Operating Margin | 11.09% | 10.96% | 12.92% | 14.05% | 15.22% | 12.42% |
Profit Margin | 9.31% | 9.35% | 10.57% | 11.91% | 11.62% | -24.21% |
Free Cash Flow Margin | - | -3.50% | 2.65% | 14.37% | 11.77% | -1.42% |
EBITDA | 583.21 | 527.33 | 509.65 | 500.21 | 488.91 | 376.54 |
EBITDA Margin | 11.91% | 11.85% | 13.96% | 15.03% | 16.22% | 13.53% |
D&A For EBITDA | 40.1 | 39.64 | 38.16 | 32.61 | 30.12 | 30.84 |
EBIT | 543.11 | 487.69 | 471.49 | 467.6 | 458.79 | 345.7 |
EBIT Margin | 11.09% | 10.96% | 12.92% | 14.05% | 15.22% | 12.42% |
Effective Tax Rate | 9.40% | 10.09% | 4.89% | 4.68% | 3.19% | - |
Revenue as Reported | 4,898 | 4,529 | 3,695 | 3,333 | 3,019 | 2,802 |
Advertising Expenses | - | 32.07 | 48.31 | 50.51 | 37.04 | 16.34 |